QURE

uniQure N.V

Oct 13 • 04:00PM ET

62.02

+0.47 0.76 %

Healthcare • Biotechnology • Netherlands • NASD

Peers: SRPT BLUE CRSP BMRN NTLA SGMO RCKT EDIT ADVM BOLD

| Held by: XBI IBB SCHA VXF ITOT LABU FRTY KOMP SCHB VHT

Index	-	P/E	-	EPS (ttm)	-3.92	Insider Own	11.32%	Shs Outstand	54.87M	Perf Week	17.22%
Market Cap	3.82B	Forward P/E	-	EPS next Y	-3.02	Insider Trans	-3.68%	Shs Float	54.63M	Perf Month	276.22%
Enterprise Value	3.97B	PEG	-	EPS next Q	-0.91	Inst Own	83.94%	Short Float	20.19%	Perf Quarter	344.27%
Income	-199.00M	P/S	266.43	EPS this Y	33.27%	Inst Trans	3.19%	Short Ratio	3.50	Perf Half Y	594.51%
Sales	14.34M	P/B	-	EPS next Y	7.92%	ROA	-30.25%	Short Interest	11.03M	Perf YTD	251.19%
Book/sh	-0.07	P/C	10.14	EPS next 5Y	59.10%	ROE	-427.47%	52W High	65.12 -4.76%	Perf Year	1005.53%
Cash/sh	6.12	P/FCF	-	EPS past 3/5Y	- -9.66%	ROIC	-38.71%	52W Low	5.23 1085.85%	Perf 3Y	206.88%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-62.73% 30.08%	Gross Margin	-25.49%	Volatility	9.25% 10.23%	Perf 5Y	64.73%
Dividend TTM	-	EV/Sales	276.55	EPS Y/Y TTM	33.77%	Oper. Margin	-1255.40%	ATR (14)	4.35	Perf 10Y	187.53%
Dividend Ex-Date	-	Quick Ratio	9.98	Sales Y/Y TTM	-48.25%	Profit Margin	-1387.98%	RSI (14)	79.26	Recom	1.15
Dividend Gr. 3/5Y	- -	Current Ratio	9.98	EPS Q/Q	40.56%	SMA20	41.05%	Beta	0.58	Target Price	73.73
Payout	-	Debt/Eq	-	Sales Q/Q	-52.71%	SMA50	129.62%	Rel Volume	0.63	Prev Close	61.56
Employees	209	LT Debt/Eq	-	Earnings	Jul 29 BMO	SMA200	259.83%	Avg Volume	3.15M	Price	62.02
IPO	Feb 05, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	22.89% -2.48%	Trades		Volume	1,966,596	Change	0.76%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-14-25	Upgrade	Mizuho	Neutral → Outperform	$30
Apr-01-25	Resumed	Chardan Capital Markets	Buy	$38
Dec-10-24	Upgrade	Raymond James	Outperform → Strong Buy
Oct-10-24	Resumed	Raymond James	Outperform	$20
Feb-29-24	Downgrade	Goldman	Buy → Neutral	$8
Dec-19-23	Downgrade	Mizuho	Buy → Neutral	$52 → $10
Mar-17-22	Upgrade	UBS	Neutral → Buy	$40
Jun-15-21	Initiated	BTIG Research	Buy	$46
May-21-21	Initiated	UBS	Neutral	$40
Apr-26-21	Resumed	Credit Suisse	Outperform	$78
Apr-01-21	Upgrade	Mizuho	Neutral → Buy	$52
Jan-07-21	Upgrade	Guggenheim	Neutral → Buy	$62
Nov-24-20	Initiated	H.C. Wainwright	Buy	$80
Nov-11-20	Initiated	Berenberg	Buy
Nov-09-20	Initiated	Jefferies	Buy	$55
Nov-04-20	Initiated	Cantor Fitzgerald	Overweight	$65
Oct-23-20	Initiated	RBC Capital Mkts	Outperform	$61
Aug-25-20	Initiated	Raymond James	Strong Buy	$75
Jul-31-20	Upgrade	Robert W. Baird	Neutral → Outperform	$57
Jun-25-20	Downgrade	Wells Fargo	Overweight → Equal Weight	$56

Show Previous Ratings

Oct-13-25 05:30AM	Why Biotech's Rally Can Last This Time (The Wall Street Journal)
Oct-08-25 05:34AM	Jim Cramer on uniQure: "This One Has Too Many Questions for Me Up Here" (Insider Monkey)
Oct-03-25 04:14PM	QURE: Why Analysts See Up to 63% Upside After 250% Single-Day Pop (MarketBeat)
Sep-30-25 12:46PM	uniQure N.V. (QURE) Reports Positive Phase I/II Results, Prepares FDA BLA Submission (Insider Monkey)
Sep-29-25 06:28PM	uniQurex (QURE) Nearly Quadruples on Stellar Results for Huntington Disease Treatment (Insider Monkey) +9.37%
04:05PM	Loading…
04:05PM	uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire)
Sep-25-25 11:38PM	uniQure Announces Pricing of Upsized $300 Million Public Offering (GlobeNewswire) +10.84%
11:07AM	QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study (Zacks)
10:23AM	Uniqure (QURE) Soars 275% on Stellar Clinical Trial for Huntington's Disease (Insider Monkey)
09:36AM	Stocks to Watch Thursday: Intel, Oracle, CarMax, Accenture (The Wall Street Journal)
09:15AM	Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus (PR Newswire)
06:24AM	Strength Seen in uniQure (QURE): Can Its 247.7% Jump Turn into More Strength? (Zacks)
Sep-24-25 04:37PM	Here's why biotech UniQure's stock just tripled, and brought ClearPoint shares up with it (MarketWatch) +247.73%
04:21PM	A Cure For Huntington's Disease? UniQure Launches Nearly 250%. (Investor's Business Daily)
04:06PM	uniQure Announces $200 Million Proposed Public Offering (GlobeNewswire)
10:23AM	Loading…
10:23AM	uniQure Stock Doubles On Promising Data From Huntington's Disease Trial (Benzinga)
07:10AM	uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding (GlobeNewswire)
07:05AM	uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington's Disease (GlobeNewswire)
Sep-18-25 09:10AM	Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics (PR Newswire)
Sep-05-25 07:05AM	uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in a-Gal A Enzyme Activity in Patients with Fabry Disease (GlobeNewswire)
Jul-31-25 09:55AM	Wall Street Analysts Think uniQure (QURE) Could Surge 142.67%: Read This Before Placing a Bet (Zacks)
Jul-29-25 08:15AM	uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -8.68%
07:13AM	UniQure: Q2 Earnings Snapshot (Associated Press Finance)
07:05AM	uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress (GlobeNewswire)
Jul-22-25 07:05AM	uniQure to Announce Second Quarter 2025 Financial Results (GlobeNewswire)
Jun-23-25 01:38AM	Lake Street: AMT-130 Could Be Game-Changer For ClearPoint (Insider Monkey)
Jun-11-25 08:00AM	uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer (GlobeNewswire)
Jun-04-25 08:55AM	Lake Street says AMT-130 could be significantly impactful for ClearPoint (TipRanks)
Jun-02-25 07:05AM	uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease (GlobeNewswire)
May-29-25 07:05AM	uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE) (GlobeNewswire)
09:05AM	Loading…
May-21-25 09:05AM	3 Top Genomics Stocks to Add to Your Portfolio in 2025 (Zacks)
May-19-25 08:00AM	Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair (GlobeNewswire) +7.37%
May-14-25 09:55AM	Wall Street Analysts See a 161.51% Upside in uniQure (QURE): Can the Stock Really Move This High? (Zacks)
May-10-25 03:04AM	uniQure NV (QURE) Q1 2025 Earnings Call Highlights: Navigating Revenue Decline with Strategic ... (GuruFocus.com)
May-09-25 08:20AM	UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:18AM	UniQure: Q1 Earnings Snapshot (Associated Press Finance)
07:05AM	uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress (GlobeNewswire)
May-05-25 04:05PM	uniQure to Announce First Quarter 2025 Financial Results (GlobeNewswire) +7.58% -27.75%
Apr-30-25 05:10AM	Deep Sail Capital Partner Q1 2025 Investor Letter (Seeking Alpha) +6.49%
Apr-29-25 09:10AM	CG Oncology, Inc. (CGON) Surges 25.0%: Is This an Indication of Further Gains? (Zacks)
Apr-21-25 09:54AM	uniQure (QURE) Moves 38.5% Higher: Will This Strength Last? (Zacks)
08:54AM	FDA grants breakthrough status to uniQures Huntingtons disease therapy (Pharmaceutical Technology)
07:30AM	uniQure: Huntington's Gene Therapy Advances, But Commercial Hurdles Keep This A Hold (Seeking Alpha)
01:56AM	uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130 (Seeking Alpha)
Apr-19-25 08:31AM	uniQure: AMT-130 For HD Progresses Forward With Q2 2025 FDA Meeting (Seeking Alpha)
Apr-17-25 07:17AM	uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease (GlobeNewswire) +38.45%
Mar-30-25 07:10AM	abrdn World Healthcare Fund Q4 2024 Commentary (Seeking Alpha)
03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
02:50AM	abrdn Healthcare Investors Q4 2024 Commentary (Seeking Alpha)
Feb-27-25 08:35AM	UniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:05AM	uniQure Announces 2024 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Feb-07-25 01:04PM	uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years (Benzinga) -9.75%
09:12AM	CSL Behring's Gene Therapy HEMGENIX (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B (PR Newswire)
Feb-03-25 07:05AM	uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease (GlobeNewswire)
Jan-30-25 07:37AM	uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS (GlobeNewswire)
Jan-27-25 05:14PM	Is uniQure N.V. (QURE) the Most Promising Growth Stock According to Wall Street Analysts? (Insider Monkey)
Jan-13-25 04:17PM	Heres Why uniQure N.V. (QURE) Is Skyrocketing (Insider Monkey)
Jan-11-25 08:01PM	Is uniQure N.V. (QURE) Among the Best Growth Stocks to Buy and Hold in 2025? (Insider Monkey)
Jan-08-25 07:05AM	uniQure Announces Pricing of its Public Offering (GlobeNewswire) -9.75%
Jan-07-25 04:49PM	uniQure Announces Proposed Public Offering (GlobeNewswire)
Dec-17-24 07:20AM	uniQure price target raised to $32 from $12 at Stifel (TipRanks) -5.40%
Dec-15-24 04:31AM	Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025? (Motley Fool)
Dec-10-24 05:11PM	UniQure Stock Doubles After Striking A Deal With The FDA For Huntington's Drug (Investor's Business Daily) +109.73%
09:34AM	UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug (Investor's Business Daily)
07:07AM	UniQure shares soar on chance of speedy approval for Huntingtons therapy (BioPharma Dive)
07:05AM	uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease (GlobeNewswire)
Nov-29-24 09:55AM	Wall Street Analysts Think uniQure (QURE) Could Surge 228.07%: Read This Before Placing a Bet (Zacks)
Nov-28-24 12:00PM	What Makes uniQure (QURE) a New Buy Stock (Zacks)
Nov-21-24 07:05AM	uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy (GlobeNewswire)
Nov-08-24 09:55AM	Wall Street Analysts Believe uniQure (QURE) Could Rally 169.18%: Here's is How to Trade (Zacks)
Nov-05-24 08:30AM	UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +8.99%
07:26AM	UniQure: Q3 Earnings Snapshot (Associated Press Finance)
07:05AM	uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Oct-29-24 10:01AM	UniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-18-24 03:03PM	State Street Corp's Strategic Reduction in uniQure NV Holdings (GuruFocus.com)
Oct-15-24 07:05AM	uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS (GlobeNewswire)
07:05AM	uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment of SOD1-ALS (GlobeNewswire)
Sep-23-24 07:05AM	uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease (GlobeNewswire) -5.78%
Aug-15-24 07:05AM	uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease (GlobeNewswire)
Aug-01-24 12:51PM	UniQure restructuring to claim 300 jobs (BioPharma Dive)
08:25AM	UniQure (QURE) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:22AM	UniQure: Q2 Earnings Snapshot (Associated Press Finance)
07:05AM	uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update (GlobeNewswire)
Jul-26-24 09:55AM	Wall Street Analysts See a 125.9% Upside in uniQure (QURE): Can the Stock Really Move This High? (Zacks)
Jul-23-24 07:05AM	uniQure Announces Closing of Sale of Manufacturing Facility to Genezen (GlobeNewswire) +5.38%
Jul-12-24 07:12AM	uniQures shares soar on positive data for Huntingtons gene therapy (Clinical Trials Arena)
Jul-10-24 09:55AM	Wall Street Analysts Think uniQure (QURE) Could Surge 195.8%: Read This Before Placing a Bet (Zacks) +51.72%
09:01AM	uniQure (QURE) Soars on New Huntington's Disease Study Data (Zacks)
05:49AM	uniQure (QURE) Surges 76.5%: Is This an Indication of Further Gains? (Zacks)
Jul-09-24 10:46AM	MULN Stock Alert: Mullen Announces EV Sale to Spencer Manufacturing (InvestorPlace) +76.46%
10:27AM	Why Is uniQure (QURE) Stock Up 51% Today? (InvestorPlace)
09:35AM	Down -29.74% in 4 Weeks, Here's Why You Should You Buy the Dip in uniQure (QURE) (Zacks)
08:05AM	UniQure stock surges on data for Huntingtons gene therapy (BioPharma Dive)
07:05AM	uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington's Disease (GlobeNewswire)
Jul-01-24 07:05AM	uniQure Announces Sale of Commercial Manufacturing Facility to Genezen (GlobeNewswire)
07:05AM	Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA (PR Newswire)
06:30AM	UniQure, with sale of plant, outsources Hemgenix manufacturing (BioPharma Dive)
Jun-03-24 07:05AM	uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntingtons Disease (GlobeNewswire) +7.68%
May-07-24 01:53PM	QURE Stock Earnings: uniQure Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:24AM	UniQure: Q1 Earnings Snapshot (Associated Press Finance)

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kapusta Matthew C	CEO, Managing Director	Sep 24 '25	Option Exercise	6.52	226,316	1,474,909	877,770	Sep 26 07:43 PM
Kapusta Matthew C	CEO, Managing Director	Sep 24 '25	Sale	41.46	226,316	9,382,473	651,454	Sep 26 07:43 PM
KLEMT CHRISTIAN	Chief Financial Officer	Sep 26 '25	Option Exercise	5.37	15,000	80,550	232,730	Sep 26 07:37 PM
KLEMT CHRISTIAN	Chief Financial Officer	Sep 24 '25	Option Exercise	13.03	3,000	39,090	220,730	Sep 26 07:37 PM
KLEMT CHRISTIAN	Chief Financial Officer	Sep 26 '25	Sale	55.00	15,000	825,000	217,730	Sep 26 07:37 PM
KLEMT CHRISTIAN	Chief Financial Officer	Sep 24 '25	Sale	40.04	3,000	120,120	217,730	Sep 26 07:37 PM
KLEMT CHRISTIAN	Officer	Sep 26 '25	Proposed Sale	55.00	15,000	825,000		Sep 26 04:04 PM
KLEMT CHRISTIAN	Officer	Sep 24 '25	Proposed Sale	40.00	3,000	120,000		Sep 24 08:01 PM
Kapusta Matthew C	Director	Sep 24 '25	Proposed Sale	41.45	226,316	9,381,750		Sep 24 07:59 PM
Abi-Saab Walid	Chief Medical Officer	Jun 27 '25	Sale	13.92	1,466	20,407	150,437	Jul 01 04:49 PM
Springhorn Jeremy P.	Director	Jun 20 '25	Sale	14.45	2,112	30,518	37,694	Jun 24 06:08 PM
POST LEONARD E	Director	Jun 20 '25	Sale	14.45	2,112	30,518	29,937	Jun 24 06:03 PM
Kaye Jack	Director	Jun 20 '25	Sale	14.45	2,112	30,518	20,439	Jun 24 05:53 PM
Jacques Rachelle Suzanne	Director	Jun 20 '25	Sale	14.45	2,112	30,518	28,346	Jun 24 05:50 PM
Gut Robert	Director	Jun 20 '25	Sale	14.45	3,336	48,205	56,879	Jun 24 05:45 PM
Balachandran Madhavan	Director	Jun 20 '25	Sale	14.45	2,112	30,518	37,697	Jun 24 05:42 PM
Meek David D.	Director	Jun 20 '25	Sale	14.45	2,112	30,518	34,190	Jun 24 05:34 PM
Potts Jeannette	Chief Legal Officer	Jun 16 '25	Sale	15.14	4,670	70,704	115,073	Jun 20 07:43 PM
Kapusta Matthew C	CEO, Managing Director	Mar 04 '25	Sale	10.29	28,341	291,629	651,454	Mar 05 05:32 PM
Abi-Saab Walid	Chief Medical Officer	Mar 04 '25	Sale	10.29	1,350	13,891	151,903	Mar 05 05:28 PM
KLEMT CHRISTIAN	Chief Financial Officer	Mar 04 '25	Sale	10.29	10,438	107,407	217,730	Mar 05 05:25 PM
Potts Jeannette	Chief Legal Officer	Mar 04 '25	Sale	10.29	7,076	72,812	119,743	Mar 05 05:21 PM
Kapusta Matthew C	CEO, Managing Director	Feb 25 '25	Sale	10.70	26,727	285,979	571,188	Feb 27 07:33 PM
Kapusta Matthew C	CEO, Managing Director	Feb 27 '25	Sale	11.32	6,717	76,036	580,795	Feb 27 07:33 PM
KLEMT CHRISTIAN	Chief Financial Officer	Feb 25 '25	Sale	10.70	14,341	153,449	152,372	Feb 27 07:29 PM
KLEMT CHRISTIAN	Chief Financial Officer	Feb 27 '25	Sale	11.32	2,916	33,009	155,168	Feb 27 07:29 PM
Kapusta Matthew C	CEO, Managing Director	Dec 10 '24	Option Exercise	14.71	100,000	1,471,000	697,915	Dec 12 04:54 PM
Kapusta Matthew C	CEO, Managing Director	Dec 10 '24	Sale	15.03	100,000	1,503,000	597,915	Dec 12 04:54 PM
Kapusta Matthew C	CEO, Managing Director	Dec 09 '24	Sale	7.63	3,418	26,079	597,915	Dec 10 05:03 PM
KLEMT CHRISTIAN	Chief Financial Officer	Dec 09 '24	Sale	7.55	1,796	13,560	166,713	Dec 10 04:54 PM
Matthew Kapusta	CEO	Dec 10 '24	Proposed Sale	15.03	100,000	1,503,491		Dec 10 04:33 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

QURE

uniQure N.V

Upgrade your FINVIZ experience